Illumina, Inc. vs Bio-Techne
Illumina, Inc. (ILMN) and Bio-Techne (TECH) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $29.2B
- Last close
- $192.82
- 12 months
- +61.7%
- Market value
- $11.4B
- Last close
- $72.67
- 12 months
- +23.7%
At a glance
- The biggest part of Illumina, Inc.'s revenue is Sequencing (92%); at Bio-Techne it is Protein Sciences (72%).
- By market value, Illumina, Inc. ($29.2B) is about 2.6 times Bio-Techne ($11.4B).
- Over the last 12 months Illumina, Inc.'s share price moved +61.7% and Bio-Techne's +23.7%; against the S&P 500 that is +56.0 points and +18.0 points.
- In their last fiscal years Illumina, Inc. kept 19.6% of revenue as net income and Bio-Techne 6.0%.
- In the last 90 days insiders reported 0 open-market purchases at Illumina, Inc. and 0 at Bio-Techne; members of Congress disclosed 1 trade in Illumina, Inc. and 0 in Bio-Techne.
- Next results: Illumina, Inc. Feb 3, 2027, Bio-Techne Feb 2, 2027.
How each one makes money: Illumina, Inc. revenue · Bio-Techne revenue
Share prices on one chart
Illumina, Inc. and Bio-Techne, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Illumina, Inc. ILMNNASDAQ · Life Sciences Tools & Services | Bio-Techne TECHNASDAQ · Life Sciences Tools & Services | |
|---|---|---|
| Size and profitability | ||
| Market value | $29.2B | $11.4B |
| Revenue, last fiscal year | $4.34B | $1.22B |
| Net income, last fiscal year | $850M | $73.4M |
| Net marginNet income as a share of revenue | 19.6% | 6.0% |
| Free cash flow | $931M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Illumina, Inc. against
Common questions
How is Illumina, Inc. different from Bio-Techne?
Illumina, Inc. (ILMN) is in Life Sciences Tools & Services on NASDAQ, with $4.34B of revenue in its last fiscal year and a net margin of 19.6%. Bio-Techne (TECH) is in Life Sciences Tools & Services on NASDAQ, with $1.22B of revenue in its last fiscal year and a net margin of 6.0%. The biggest part of Illumina, Inc.'s revenue is Sequencing (92%); at Bio-Techne it is Protein Sciences (72%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Illumina, Inc. and Bio-Techne compare in size?
Illumina, Inc. has the larger market value: Illumina, Inc. $29.2B and Bio-Techne $11.4B, at the last close.
Whose share price rose more over the last 12 months, ILMN or TECH?
Over the last 12 months Illumina, Inc. moved +61.7% and Bio-Techne +23.7%. Past price moves say nothing about the future.
Which has had more insider buying, Illumina, Inc. or Bio-Techne?
Since 2006, Illumina, Inc. insiders reported 33 open-market purchases against 7 for Bio-Techne. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ILMN or TECH?
In the last 12 months, members of Congress disclosed 2 trades in Illumina, Inc. (ILMN) and 6 in Bio-Techne (TECH).
When did insiders last buy ILMN and TECH?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Illumina, Inc. pageBio-Techne pageRare insider trades this weekAll comparisons
https://oqro.io/compare/ilmn-vs-tech







